司美格鲁肽联合达格列净对肥胖型糖尿病患者血糖、血脂水平的影响研究

Effect of Semaglutide Combined with Dapagliflozin on Blood Glucose and Blood Lipids Level in Obese Diabetic Patients

目的分析司美格鲁肽联合达格列净对肥胖型糖尿病患者血糖、血脂水平的影响。方法选取2020年2月—2023年2月泉州市惠安县医院收治的79例肥胖型糖尿病患者为研究对象,以随机数表法分为对照组(n=39)与观察组(n=40)。对照组采用达格列净治疗,观察组采用司美格鲁肽联合达格列净进行治疗。对比两组血糖、血脂指标及不良反应发生情况。结果治疗前,两组血糖、血脂指标比较,差异无统计学意义(P均>0.05);治疗后,两组血糖指标、三酰甘油(Triglyceride,TG)、总胆固醇(Total Cholesterol,TC)、低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol,LDL-C)水平低于治疗前,高密度脂蛋白胆固醇(High Density Li⁃poprotein Cholesterol,HDL-C)水平高于治疗前,且观察组血糖指标、TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P均<0.05)。两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论司美格鲁肽联合达格列净治疗肥胖型糖尿病的临床效果更佳,能有效降低患者的血糖与血脂水平,且联合用药安全性高。

Objective To analyze the effect of semaglutide combined with dapagliflozin on blood glucose and blood lipids level in obese diabetic patients.Methods A total of 79 obese diabetic patients admitted to Quanzhou Hui'an County hospital from February 2020 to February 2023 were selected as the study objects,and they were divided into control group(n=39)and observation group(n=40)according to random number table method.The control group were treated with dapagliflozin,and the observation group were treated with emaglutide combined with dapagliflozin.Bio⁃chemical indexes of blood glucose and blood lipid,and the rate of adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in blood glucose and blood lipid indexes be⁃tween the two groups(both P>0.05).After treatment,the blood glucose index,level of triglyceride(TG),total choles⁃terol(TC)and low density lipoprotein cholesterol(LDL-C)in two groups were lower than those before treatment,and level of high density lipoprotein cholesterol(HDL-C)was higher than those before treatment,while the blood glucose indexes,TC,TG and LDL-C levels in observation group were lower than those in control group,HDL-C level was higher than that in control group,and the differences were statistically significant(all P<0.05).Comparison of the total incidence of adverse reactions,there was no significant difference between the two groups(P>0.05).Conclusion Semaglutide combined with dapagliflozin has better clinical effect in the treatment of obese diabetes mellitus,which can effectively reduce blood glucose and blood lipids in patients,and the combined drug has high safety.